ALS drug safety check: 96-Week extension trial launches
NCT ID NCT07571200
First seen May 07, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study looks at the long-term safety of different treatments for amyotrophic lateral sclerosis (ALS). It is for people who have already completed a related earlier study. The goal is to monitor side effects and tolerability over at least 96 weeks. About 32 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre
Montreal, H4A 3J1, Canada
Contact Phone: •••-•••-••••
Contact
-
Sunnybrook Research Institute
Toronto, M4N 3M5, Canada
Contact
-
UZ Leuven
Leuven, 3000, Belgium
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.